Exploring Antisense Oligonucleotide Therapy
Exploring Antisense Oligonucleotide Therapy reveals several interesting facts.
- Frank Rigo, PhD, Isis Pharmaceuticals, discusses Exon Skipping.
- Adrian Krainer is the St. Giles Foundation Professor at Cold Spring Harbor Laboratory. He received a B.A. cum laude in ...
- Discover the groundbreaking potential of
- For this week's episode of our “How Does It Work?” series, we dive further into exploring
- Can we change how a gene is read without changing the DNA itself? This episode explains
In-Depth Information on Antisense Oligonucleotide Therapy
An overview of Chair, Jinsy A. Andrews, MD, MSc, FAAN, discusses amyotrophic lateral sclerosis in this CME activity titled “A Visual Exploration ... Anne Smith, Executive Director, Clinical Development at Ionis Pharmaceuticals Anne Smith, PhD, is an Executive Director of ... In this week's installment of our “How Does It Work?” video series, we'll explore
PUBLISHED 05/01/2019 In this episode Dr. Steve Perrin, CEO at the ALS
Stay tuned for more updates related to Antisense Oligonucleotide Therapy.
